These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7708360)

  • 1. Free radical mechanisms in schizophrenia and tardive dyskinesia.
    Cadet JL; Kahler LA
    Neurosci Biobehav Rev; 1994; 18(4):457-67. PubMed ID: 7708360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free radicals, antioxidant defense systems, and schizophrenia.
    Wu JQ; Kosten TR; Zhang XY
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():200-6. PubMed ID: 23470289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E.
    Elkashef AM; Wyatt RJ
    Schizophr Bull; 1999; 25(4):731-40. PubMed ID: 10667743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.
    Yao JK; Reddy RD; van Kammen DP
    CNS Drugs; 2001; 15(4):287-310. PubMed ID: 11463134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms.
    Lohr JB; Cadet JL; Lohr MA; Larson L; Wasli E; Wade L; Hylton R; Vidoni C; Jeste DV; Wyatt RJ
    Schizophr Bull; 1988; 14(2):291-6. PubMed ID: 2904696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current status of tardive dyskinesia.
    Sachdev PS
    Aust N Z J Psychiatry; 2000 Jun; 34(3):355-69. PubMed ID: 10881961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.
    Inada T; Koga M; Ishiguro H; Horiuchi Y; Syu A; Yoshio T; Takahashi N; Ozaki N; Arinami T
    Pharmacogenet Genomics; 2008 Apr; 18(4):317-23. PubMed ID: 18334916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of spirulina maxima on the haloperidol induced tardive dyskinesia and oxidative stress in rats.
    Thaakur SR; Jyothi B
    J Neural Transm (Vienna); 2007 Sep; 114(9):1217-25. PubMed ID: 17530160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vulnerability to tardive dyskinesia development in schizophrenia: an FDG-PET study of cerebral metabolism.
    Szymanski S; Gur RC; Gallacher F; Mozley LH; Gur RE
    Neuropsychopharmacology; 1996 Dec; 15(6):567-75. PubMed ID: 8946431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis.
    Gunne LM; Häggström JE; Sjöquist B
    Nature; 1984 May 24-30; 309(5966):347-9. PubMed ID: 6727989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antioxidant treatment of tardive dyskinesia.
    Rotrosen J; Adler L; Lohr J; Edson R; Lavori P
    Prostaglandins Leukot Essent Fatty Acids; 1996 Aug; 55(1-2):77-81. PubMed ID: 8888127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free radical mechanisms in the central nervous system: an overview.
    Cadet JL
    Int J Neurosci; 1988 May; 40(1-2):13-8. PubMed ID: 2840405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tardive dyskinesia and substrates of energy metabolism in CSF.
    Goff DC; Tsai G; Beal MF; Coyle JT
    Am J Psychiatry; 1995 Dec; 152(12):1730-6. PubMed ID: 8526238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative mechanisms and tardive dyskinesia.
    Lohr JB; Kuczenski R; Niculescu AB
    CNS Drugs; 2003; 17(1):47-62. PubMed ID: 12467492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin.
    Tripodianakis J; Markianos M; Garelis E
    Biol Psychiatry; 1983 Mar; 18(3):337-45. PubMed ID: 6132625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan.
    Rizos EN; Chatziioannou S; Douzenis A; Siafakas N; Katsantoni E; Nikolaidou P; Papathanasiou M; Lykouras L
    Eur Neuropsychopharmacol; 2010 Feb; 20(2):132-6. PubMed ID: 19740630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements.
    Zhang XY; Zhou DF; Cao LY; Chen DC; Zhu FY; Wu GY
    Schizophr Res; 2003 Aug; 62(3):245-50. PubMed ID: 12837521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral-type benzodiazepine-binding sites in platelets of schizophrenics with and without tardive dyskinesia.
    Weizman R; Tanne Z; Karp L; Tyano S; Gavish M
    Life Sci; 1986 Aug; 39(6):549-55. PubMed ID: 3016444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.